AmeritoxSM, a national leader in medication monitoring solutions, presented new research showing that in one out of three samples of patients prescribed stimulants to treat attention-deficit/hyperactivity (ADHD) disorder the prescribed drug was not detected. Members of Ameritox's Medical Affairs team prepared the data for attendees at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting, held in Washington, where conference organizers highlighted the Ameritox report for attendees.